RARA CRAFT DATABASE for FDA Medical Devices
510(k)K253367

FDA DEVICE FACTS

EliA CTD 13 Screen

Phadia AB

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJune 25, 2026PRODUCT CODELLL

Indications for use

EliA CTD 13 Screen is intended for the in vitro qualitative detection of antinuclear IgG antibodies in human serum as an aid in the diagnosis of systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), systemic sclerosis (SSc), polymyositis (PM), dermatomyositis (DM) and mixed connective tissue disease (MCTD), in conjunction with other laboratory and clinical findings. EliA CTD 13 Screen detects antibodies against RNP70, U1RNP-A, U1RNP-C, SS-A/Ro60, SS-A/Ro52, SS-B/La, Centromere B, Scl-70, Jo-1, RNA Pol III, Rib-P, Sm and dsDNA. EliA CTD 13 Screen uses the EliA IgG method.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 22, 2026